Type: Observational

Status of the trial: Active, Not recruiting

Orphan Drug Recognition: NA

Inclusion

• Opening Date: 2017-08-01
• Closing Date: 2021-12-31

Criteria

Inclusion: Participants with clinical diagnosis of rod-cone degeneration and at least 2 pathogenic or likely pathogenic mutations in USH2A gene; age ≥ 8 years

Exclusion: Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A; Expected to enter experimental treatment trial at any time during this study; History

More information